• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

ASCRS Live: Mark Baum shares updates from Harrow

Video

Mark Baum, CEO of Harrow discussed the recent launch of Iheezo and other key updates from the company with the Ophthalmology Times© team at the ASCRS annual meeting in San Diego.

Mark Baum, CEO of Harrow discussed the recent launch of Iheezo and other key updates from the company with the Ophthalmology Times© team at the ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Mark Baum:

Hi, I'm Mark Baum, Chief Executive Officer of Harrow. Many of you may not be familiar with Harrow, but we've been in the ophthalmic pharmaceutical business now for about 10 years. You may not know the name Harold, but you probably know many of our products. And by the way, we're a US focused serving ophthalmologists and optometrists in the US. But you may know us because of some of our brands like infamous RX, the leader in ophthalmic compounding in the United States. Our products are made at the highest federal manufacturing standards. And now, we started with no customers, and today we serve more than 10,000 ophthalmologists and optometrists in the United States.


We recently have expanded our portfolio dramatically. In addition to these incredibly useful, affordable compounded medications that many of you have enjoyed now, for so long. We are expanding our portfolio to brand new products. We recently completed a transaction, actually two transactions, with Novartis to acquire 9 of their products. So when you think of Triesence, when you think of Ilevro, Nevanac, Vigamox, those are brands that now are part of the Harrow portfolio.


And, this year at ASCRS, we're really excited because in addition to the portfolio that I've mentioned, we are debuting our newest product, Iheezo. It is the first new topical anesthetic in the US market. That's FDA approved in more than 14 years, and it has a very broad label. Doctors are using it for intravitreal injections, as well as to anesthetize the eye for cataract surgery, and importantly, it has its own permanent J-code, J-code J-2403. So it is the only reimbursable topical anesthetic in the US market.


So amazing things are happening at Harrow. The company is doing better than we've ever done. We're so fortunate to be able to serve so many of you, and we're excited about this meeting and really excited about the debut of Iheezo. Give it a try. Thank you

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.